These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 20799462)

  • 1. Regulatory aspects of clinical trials in children.
    Mentzer D
    Arb Paul Ehrlich Inst Bundesinstitut Impfstoffe Biomed Arzneim Langen Hess; 2009; 96():203-7; discussion 207-9. PubMed ID: 20799462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacovigilance during the pre-approval phases: an evolving pharmaceutical industry model in response to ICH E2E, CIOMS VI, FDA and EMEA/CHMP risk-management guidelines.
    Hartford CG; Petchel KS; Mickail H; Perez-Gutthann S; McHale M; Grana JM; Marquez P
    Drug Saf; 2006; 29(8):657-73. PubMed ID: 16872240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The EU paediatric regulation: effects on paediatric psychopharmacology in Europe.
    Stoyanova-Beninska VV; Wohlfarth T; Isaac M; Kalverdijk LJ; van den Berg H; Gispen-de Wied C
    Eur Neuropsychopharmacol; 2011 Aug; 21(8):565-70. PubMed ID: 20621456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progress review of the European Paediatric Regulatory Framework after six years of implementation.
    Mentzer D
    Int J Pharm; 2014 Aug; 469(2):240-3. PubMed ID: 24613178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medicines for children licensed by the European Agency for the Evaluation of Medicinal Products.
    Ceci A; Felisi M; Catapano M; Baiardi P; Cipollina L; Ravera S; Bagnulo S; Reggio S; Rondini G
    Eur J Clin Pharmacol; 2002 Nov; 58(8):495-500. PubMed ID: 12451425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. European perspectives on pediatric formulations.
    Breitkreutz J
    Clin Ther; 2008 Nov; 30(11):2146-54. PubMed ID: 19108802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug development in oncology: a regulatory perspective.
    Augustus S
    Am J Ther; 2011 Jul; 18(4):323-31. PubMed ID: 20335790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of the European paediatric legislation in paediatric rheumatology: past, present and future.
    Ruperto N; Vesely R; Saint-Raymond A; Martini A;
    Ann Rheum Dis; 2013 Dec; 72(12):1893-6. PubMed ID: 23962457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Are children getting the right drugs?].
    Bratlid D
    Tidsskr Nor Laegeforen; 2005 Dec; 125(23):3290-2. PubMed ID: 16327857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. European paediatric research and children's therapeutic needs. A trial review.
    Pandolfini C; Bonati M
    Acta Paediatr; 2008 Sep; 97(9):1232-7. PubMed ID: 18489618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biosimilars approval process.
    Zuñiga L; Calvo B
    Regul Toxicol Pharmacol; 2010 Apr; 56(3):374-7. PubMed ID: 19925842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Developing paediatric medicines: identifying the needs and recognizing the challenges.
    Ernest TB; Elder DP; Martini LG; Roberts M; Ford JL
    J Pharm Pharmacol; 2007 Aug; 59(8):1043-55. PubMed ID: 17725846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. European Union pediatric legislation jeopardizes worldwide, timely future advances in the care of children with cancer.
    Rose K
    Clin Ther; 2014 Feb; 36(2):163-77. PubMed ID: 24529288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The development of medicines for children. Part of a series on Pediatric Pharmacology, guest edited by Gianvincenzo Zuccotti, Emilio Clementi, and Massimo Molteni.
    Rocchi F; Tomasi P
    Pharmacol Res; 2011 Sep; 64(3):169-75. PubMed ID: 21376810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pain management in the paediatric population: the regulatory situation in Europe.
    Fortinguerra F; Maschi S; Clavenna A; Bonati M
    Arch Dis Child; 2010 Sep; 95(9):749-53. PubMed ID: 20584850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anticancer Drug Development: The Way Forward.
    Connors T
    Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pediatric clinical trial experience: government, child, parent and physician's perspective.
    Salazar JC
    Pediatr Infect Dis J; 2003 Dec; 22(12):1124-7. PubMed ID: 14688585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 Jun; 21(12):2397-406. PubMed ID: 12692171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical trials with minors in Germany--effects of the 12th amendment to the German Drug Code on the numbers of applications to Institutional Review Boards (IRB)].
    Kölch M; Märsch C; Fegert JM; Lippert HD
    Gesundheitswesen; 2009 Mar; 71(3):127-33. PubMed ID: 19221985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CIOMS and ICH initiatives in pharmacovigilance and risk management: overview and implications.
    Tsintis P; La Mache E
    Drug Saf; 2004; 27(8):509-17. PubMed ID: 15154824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.